Risk Analysis Report: Dendrite Clinical Systems Limited

1. Risk Rating: MEDIUM

Justification: The company demonstrates a long operating history and returned to profitability in FY2025, but exhibits significant balance sheet vulnerabilities including a large undisclosed creditor balance, declining cash reserves, and rapidly growing trade debtors that warrant careful scrutiny. Net current assets, while positive, provide limited buffer against the substantial creditor position.

2. Key Concerns

Concern 1: Large and Opaque "Other Creditors" Balance Other creditors stand at £1,463,682, representing approximately 85% of total current liabilities and 60% of total assets. This balance has only decreased marginally from £1,539,876 in the prior year. The accounts provide no breakdown or explanation of what this balance comprises. For a company with 23 employees and £125 in share capital, this is a material figure that could represent related-party obligations, deferred income, or other significant commitments that directly impact solvency assessment.

Concern 2: Trade Debtors Increasing Rapidly While Cash Declines Trade debtors surged 49.5% from £818,493 to £1,223,895 year-on-year, while cash declined from £1,221,503 to £1,072,279. This divergence may indicate revenue growth, but equally could signal deteriorating collection practices or extended payment terms to customers. With debtors now representing approximately 50% of current assets, the quality and collectibility of this balance is critical to liquidity. The absence of any disclosed bad debt provision is notable given this concentration.

Concern 3: Thin Capitalization and Director Loan Arrangements Share capital remains at just £125, making the company heavily reliant on retained profits and the share premium account for equity. Additionally, directors P Walton and N McCann owe the company £7,999 and £9,999 respectively on interest-free terms with no set repayment dates. While not material in absolute terms, these arrangements represent related-party transactions on preferential terms and raise questions about governance rigor.

3. Positive Indicators

Profitability Recovery: The profit and loss reserve moved from a deficit of (£124,176) to a positive balance of £141,423, indicating the company generated approximately £265,599 in retained profit during FY2025. This represents a meaningful recovery from the prior year's losses.

Long Operating History: Incorporated in 1992, the company has over 30 years of continuous operation in the clinical systems sector, suggesting a sustainable business model and established market position.

Unqualified Audit Opinion: The financial statements received an unqualified audit report from James Cowper Kreston Audit, signed 15 December 2025, providing independent verification of the financial position.

Regulatory Compliance: All filings are current with no overdue accounts or confirmation statements. The company maintains its Active status with no indications of insolvency proceedings.

Defined Contribution Pension: The company operates a defined contribution scheme only, eliminating any defined benefit pension liability risk that could affect long-term solvency.

4. Due Diligence Notes

1. Composition of "Other Creditors": The £1.46m other creditors balance requires immediate investigation. Request full breakdown from management — determine whether this represents deferred income (common in software/maintenance contracts), related-party balances, accruals, or other obligations. The nature of this balance fundamentally affects solvency assessment.

2. Trade Debtors Ageing Analysis: Obtain a detailed ageing profile of the £1.22m trade debtors. Assess whether the 49.5% increase is revenue-driven or reflects deteriorating collections. Compare debtor days to prior periods and industry benchmarks.

3. Revenue and Margin Trends: As a small company, Dendrite has opted not to file its profit and loss account. Request full P&L details to understand revenue trajectory, gross margins, and operating cost structure. The employee count decreased from 24 to 23, which may indicate cost management or attrition concerns.

4. Cash Flow Trajectory: Cash has declined 28% from its 2023 peak of £1,487,676 to £1,072,279 in 2025. Understand whether this reflects investment, dividend extraction, or operational cash burn. The two-year declining trend requires monitoring.

5. Deferred Tax Asset Realizability: The £50,000 deferred tax asset (representing tax losses carried forward) has remained unchanged for at least two years. Clarify the timeline for utilization and whether any impairment assessment has been performed.

6. Related Party Transactions Beyond Director Loans: Given that Dr P.K.H. Walton holds 25-50% of shares and voting rights, and the large "other creditors" balance, investigate whether any related-party obligations exist within that creditor figure.

7. Historical Net Asset Volatility: Net assets have shown significant swings (from £199,927 in 2019 to £923,509 in 2023, then dropping to £475,924 in 2024 before recovering to £741,523 in 2025). Understand the drivers of this volatility — particularly the FY2024 decline — to assess earnings stability.

8. Client Concentration: With 23 employees and over £1.2m in trade debtors, assess whether revenue is concentrated among a small number of clients, which would increase business risk.